Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 2/20 | 0.32 |
| ▸ | CCR5 | P51681 | 2/20 | 0.32 |
| ▸ | CCR8 | P51685 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17326027 | 0.80 | MAPK1 (0.33) | — | |
| SCHEMBL23333325 | 0.80 | CCR1 (0.40) | ADRA2AADRA2BADRA2CADRA1DKDM4E | |
| SCHEMBL18256848 | 0.77 | KDM4E (0.33) | KDM4EGAACCR1CCR5CCR8 | |
| SCHEMBL17326038 | 0.77 | NQO2 (0.33) | CYP1A2 | |
| SCHEMBL20699186 | 0.76 | NQO2 (0.38) | CCR1CCR5CCR8CYP2A6 | |
| SCHEMBL1126301 | 0.75 | NQO2 (0.38) | ADRA2AADRA2BADRA2CADRA1DKDM4E | |
| SCHEMBL18779067 | 0.74 | LMNA (0.32) | KDM4EGAACCR1CCR5CCR8 | |
| SCHEMBL20699181 | 0.72 | MAPK1 (0.38) | KDM4ECCR1CCR5CCR8 | |
| SCHEMBL18779099 | 0.69 | ADRA2A (0.43) | ADRA2AADRA2BADRA2CADRA1DCCR1 | |
| SCHEMBL6422445 | 0.69 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CADRA1DKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957269-B2 | S-imino-S-oxo iminothiazine compounds as bace inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170260181-A1 | S-IMINO-S-OXO IMINOTHIAZINE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9732088-B2 | C2-carbocyclic iminothiazine dioxides as BACE inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170114065-A1 | C2-CARBOCYCLIC IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260181-A1 | S-IMINO-S-OXO IMINOTHIAZINE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, BACE2, APP | ADRA2A 199/4885ADRA2B 136/4885ADRA2C 435/4885 |
| US-20170114065-A1 | C2-CARBOCYCLIC IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE2, BACE1, APP | ADRA2A 1470/4885ADRA2B 1407/4885ADRA2C 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.